Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab Open-label Extension in Severe Eosinophilic Asthma
CTR20221843Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of depemokimab in eosinophilic asthma (EA), sponsored by GSK. Primary endpoints: Incidence of adverse events and serious adverse events over 52 weeks and Incidence of immunogenicity to GSK3511294 (ADA and neutralizing antibodies). Started Jul 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20221843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221843.